March 19, 2004—Access CardioSystems recently announced its Biphasic WaveControl clinical study results. The study demonstrated 100% first shock efficacy for Biphasic WaveControl, the Access CardioSystems proprietary biphasic waveform, utilized in the AccessAED and AccessALS automated external defibrillators. The study was conducted on sixty (60) patients at John Hopkins University Hospital (Baltimore, MD), St. Elizabeth’s Medical Center (Boston, MA), and the University of Rome (Rome, Italy).
The study was performed on patients undergoing routine arrhythmia testing or evaluation of an implantable defibrillator. As a part of this electrophysiology testing, ventricular fibrillation (VF), the most common cause of sudden cardiac arrest, was induced in each patient.
Once VF was induced, the AccessAED was utilized to defibrillate the patients’ heart. Upon defibrillation, the Biphasic WaveControl waveform automatically measures the patient’s impedance level and compensates for it, maximizing clinical safety and efficacy prior to shock administration, ensuring delivery of the most appropriate energy level for that patient.
One hundred percent (100%) of the patients were successfully defibrillated by the AccessAED on the first shock at the device’s lowest energy setting; 200 Joules. No adverse effects were observed after defibrillation with the AccessAED.
Access CardioSystems’ AccessAED is the smallest and lightest, full-energy AED available, weighing just 2.8 lbs, and measuring only 3.0″ x 7.3″ x 4.3″ when fully equipped. Its ease of use, configurable features and portability make it the ideal AED for all AED users and in all market segments.
AccessAED reports that an estimated 350,000 deaths that occur each year in the United States alone, due to Sudden Cardiac Arrest (SCA). Many of these deaths can be prevented if effective defibrillation is administered within 3 to 5 minutes of the SCA. The American Heart Association (AHA) actively promotes the use of AEDs and supports public access to these devices. For every minute saved, survival increases by 10%. Only early access can effectively prevent death from SCA.
For more information, contact Access CardioSystems.
